Teriflunomide — Membership Pricing

Other medications in Neurological

• Tiagabine
• Trihexyphenidyl
• Ubrogepant
• Valproate IV
• Vigabatrin
• Zonisamide
• Alemtuzumab
• Amantadine

About Teriflunomide

Teriflunomide is a vital medication for individuals managing relapsing forms of multiple sclerosis (MS). At TheDrugClub, we understand the importance of affordable access to critical treatments. Multiple sclerosis (MS) is a chronic, often debilitating disease that affects the brain, spinal cord, and optic nerves, which collectively form the central nervous system. In MS, the immune system mistakenly attacks the protective sheath (myelin) that covers nerve fibers, leading to communication problems between your brain and the rest of your body. This can result in a wide range of symptoms, including numbness, weakness, vision problems, and difficulty with coordination. ### What Teriflunomide Treats

Teriflunomide, often known by its brand name Aubagio, is an oral medication specifically approved to treat relapsing forms of multiple sclerosis. This includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. By taking teriflunomide, patients can significantly reduce the frequency and severity of MS relapses, slow the progression of physical disability, and decrease the number of new or enlarging brain lesions observed on MRI scans. ### How Teriflunomide Works

Teriflunomide is an immunomodulatory agent. It works by inhibiting an enzyme called dihydroorotate dehydrogenase, which is essential for the production of pyrimidines. Pyrimidines are crucial building blocks for DNA and RNA, and rapidly dividing cells, particularly certain immune cells (like T and B lymphocytes involved in the autoimmune attack in MS), rely heavily on this pathway. By blocking this enzyme, teriflunomide reduces the proliferation of these activated immune cells, effectively dampening the immune system's attack on the myelin sheath in the central nervous system. This helps to reduce inflammation and protect nerve cells from damage, thereby managing the progression of MS. ### Understanding Typical Costs

Specialty medications like teriflunomide are often life-changing, but they also come with a significant price tag. Without adequate insurance coverage or assistance programs, the cost of teriflunomide can be prohibitive, often running into several thousand dollars per month. This substantial financial burden can be a major barrier to consistent treatment, impacting both the patient's health and their financial stability.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Teriflunomide is approved for (FDA label)

Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Teriflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: August 26, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Teriflunomide (FDA label)

WARNING: HEPATOTOXICITY and EMBRYOFETAL TOXICITY Hepatotoxicity Clinically significant and potentially life-threatening liver injury, including acute liver failure requiring transplant, has been reported in patients treated with teriflunomide in the postmarketing setting [see Warnings and Precautions ( 5.1 )] . Concomitant use of teriflunomide with other hepatotoxic drugs may increase the risk of severe liver injury. Obtain transaminase and bilirubin levels within 6 months before initiation of teriflunomide therapy. Monitor ALT levels at least monthly for six months after starting teriflunomide [see Warnings and Precautions ( 5.1 )] . If drug induced liver injury is suspected, discontinue teriflunomide and start an accelerated elimination procedure with cholestyramine or charcoal [see Warnings and Precautions ( 5.3 )] . Teriflunomide is contraindicated in patients with severe hepatic impairment [see Contraindications ( 4 )] . Patients with pre-existing liver disease may be at increased risk of developing elevated serum transaminases when taking teriflunomide. Embryofetal Toxicity Teriflunomide is contraindicated for use in pregnant women and in females of reproductive potential who are not using effective contraception because of the potential for fetal harm. Teratogenicity and embryolethality occurred in animals at plasma teriflunomide exposures lower than that in humans. Exclude pregnancy before the start of treatment with teriflunomide in females of reproductive potential. Advise females of reproductive potential to use effective contraception during teriflunomide treatment and during an accelerated drug elimination procedure after teriflunomide treatment.

Source: FDA prescribing information (DailyMed). Set ID: c424959d-00c9-4e76-aba6-cc7464d8e903. SPL document ID: ab872943-4035-4a09-afd2-3a338daf6f64. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Teriflunomide (FDA label)

Teriflunomide is available as 7 mg and 14 mg tablets. The 7 mg tablet is light blue, round shaped, film-coated, debossed with "TV" on one side of the tablet and "Y13" on the other side of the tablet. Each tablet contains 7 mg of teriflunomide. The 14 mg tablet is blue, round shaped, film-coated, debossed with "TV" on one side of the tablet and "Y12" on the other side of the tablet. Each tablet contains 14 mg of teriflunomide. 7 mg and 14 mg film-coated tablets ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: c424959d-00c9-4e76-aba6-cc7464d8e903. SPL document ID: ab872943-4035-4a09-afd2-3a338daf6f64. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Teriflunomide (FDA label)

The following clinically significant adverse reactions are described elsewhere in the prescribing information: Hepatotoxicity [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )] Bone Marrow Effects/Immunosuppression Potential/Infections [see Warnings and Precautions ( 5.4 )] Hypersensitivity Reactions [see Contraindications ( 4 ) and Warnings and Precautions ( 5.5 )] Serious Skin Reactions [see Warnings and Precautions ( 5.6 )] Drug Reaction with Eosinophilia and Systemic Symptoms [see Warnings and Precautions ( 5.7 )] Cutaneous or Mucocutaneous Ulcers and Impaired Wound Healing [see Warnings and Precautions ( 5.8 )] Peripheral Neuropathy [see Warnings and Precautions ( 5.9 )] Increased Blood Pressure [see Warnings and Precautions ( 5.10 )] Respiratory Effects [see Warnings and Precautions ( 5.11 )] Pancreatitis in Pediatric Patients [see Warnings and Precautions ( 5.12 )] Most common adverse reactions (≥10% and ≥2% greater than placebo): headache, diarrhea, nausea, alopecia, increase in ALT. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: c424959d-00c9-4e76-aba6-cc7464d8e903. SPL document ID: ab872943-4035-4a09-afd2-3a338daf6f64. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Teriflunomide (FDA label)

Teriflunomide is contraindicated in/with: Patients with severe hepatic impairment [see Warnings and Precautions ( 5.1 )] . Pregnant women and females of reproductive potential not using effective contraception. Teriflunomide may cause fetal harm [see Warnings and Precautions ( 5.2 , 5.3 ) and Use in Specific Populations ( 8.1 )] . Patients with a history of a hypersensitivity reaction to teriflunomide, leflunomide, or to any of the inactive ingredients in teriflunomide tablets. Reactions have included anaphylaxis, angioedema, and serious skin reactions [see Warnings and Precautions ( 5.5 )] . Coadministration with leflunomide [see Clinical Pharmacology ( 12.3 )] . Severe hepatic impairment ( 4 , 5.1 ) Pregnancy ( 4 , 5.2 , 8.1 ) Hypersensitivity ( 4 , 5.5 ) Current leflunomide treatment ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: c424959d-00c9-4e76-aba6-cc7464d8e903. SPL document ID: ab872943-4035-4a09-afd2-3a338daf6f64. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Teriflunomide (FDA label)

Elimination of teriflunomide can be accelerated by administration of cholestyramine or activated charcoal for 11 days. ( 5.3 ) Teriflunomide may decrease WBC. A recent CBC should be available before starting teriflunomide. Monitor for signs and symptoms of infection. Consider suspending treatment with teriflunomide in case of serious infection. Do not start teriflunomide in patients with active infections. ( 5.4 ) Stop teriflunomide if patient has anaphylaxis, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms; initiate rapid elimination. ( 5.3 , 5.5 , 5.6 , 5.7 ) Cutaneous or mucocutaneous ulcers/impaired wound healing: If ulcer or impaired wound healing is suspected, consider discontinuation of teriflunomide treatment and an accelerated drug elimination procedure. ( 5.8 ) If patient develops symptoms consistent with peripheral neuropathy, evaluate patient and consider discontinuing teriflunomide. ( 5.9 ) Teriflunomide may increase blood pressure.

Source: FDA prescribing information (DailyMed). Set ID: c424959d-00c9-4e76-aba6-cc7464d8e903. SPL document ID: ab872943-4035-4a09-afd2-3a338daf6f64. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Teriflunomide (FDA label)

Effect of Teriflunomide on CYP2C8 Substrates Teriflunomide is an inhibitor of CYP2C8 in vivo . In patients taking teriflunomide, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology ( 12.3 )] . Effect of Teriflunomide on Warfarin Coadministration of teriflunomide with warfarin requires close monitoring of the international normalized ratio (INR) because teriflunomide may decrease peak INR by approximately 25%. Effect of Teriflunomide on Oral Contraceptives Teriflunomide may increase the systemic exposures of ethinylestradiol and levonorgestrel.

Source: FDA prescribing information (DailyMed). Set ID: c424959d-00c9-4e76-aba6-cc7464d8e903. SPL document ID: ab872943-4035-4a09-afd2-3a338daf6f64. Label effective date: August 26, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.